$75 million settlement

Akzo Nobel confirmed today that it and its US human healthcare business, Organon USA, have settled the remaining claims in an antitrust litigation involving its Remeron anti-depressant in the US.


Akzo Nobel, the international pharmaceuticals, coatings and chemicals company, confirmed today that it and its US human healthcare business, Organon USA, have settled the remaining claims in an antitrust litigation involving its Remeron anti-depressant in the United States.



This settlement, with a proposed class of drug wholesalers who purchased Remeron directly from Organon, amounts to $75 million.



It resolves the final claims in a series of lawsuits alleging that the company’s conduct involving a patent for the use of Remeron in combination with so-called SSRIs delayed the market introduction of mirtazapine (the generic version of Remeron) and violated the antitrust laws.



Akzo Nobel said in a statement that its actions in obtaining and enforcing its intellectual property rights were appropriate, but given the time, costs and risks involved in defending this action, the company took the opportunity to resolve the matter.



The settlement is subject to certain conditions including, but not limited to, approval by the Federal District Court of New Jersey.